Non-Oncology Precision Medicine Market
Non-Oncology Precision Medicine Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Non-Oncology Precision Medicine Market Size and Growth
The Non-Oncology Precision Medicine market is poised for significant growth, driven by advancements in genomics, personalized therapies, and demand for targeted treatments. The market size is projected to reach approximately $35 billion by 2025, fueled by increasing applications in cardiology, neurology, and rare diseases, along with supportive regulatory frameworks.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Abbott Laboratories
◍ Agilent Technologies, Inc.
◍ Asuragen, Inc.
◍ Almac Group
◍ AstraZeneca PLC
◍ Bristol Myers Squibb
◍ bioMérieux SA.
◍ BGI
◍ Danaher Corp.
◍ Illumina, Inc.
◍ Invitae Corporation
◍ Opko Health, Inc.
◍ Teva Pharmaceutical Industries Ltd.
The Non-Oncology Precision Medicine market includes companies like Abbott Laboratories, Illumina, and Agilent Technologies, focusing on genomic testing and personalized therapies for various diseases. These firms enhance market growth via innovative diagnostic solutions, collaborations, and integrated healthcare approaches. Selected sales revenues are:
- Illumina: ~$3.2 billion
- Abbott Laboratories: ~$43 billion
- Danaher: ~$31 billion
Request Sample Report
Market Segmentation
By Application
Infectious Diseases
Neurology
Cardiovascular ◍ Lifestyle and Endocrinology ◍ Gastroenterology ◍ Others
By Product
◍ Applied Sciences
Precision Diagnostics
Digital Health and Information Technology
Precision Therapeutics
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
